Irritable-Bowel Syndrome Animations

Discovery Could Improve Understanding Of Ulcerative Colitis, Lead To New Therapies
An international team led by University of Pittsburgh School of Medicine researchers has identified genetic markers associated with risk for ulcerative colitis. The findings, which appear as an advance online publication of the journal Nature Genetics, bring researchers closer to understanding the biological pathways involved in the disease and may lead to the development of new treatments that specifically target them.

GeneThera Will Test Milk And Dairy Products Due To Evidence Linking Johne's Disease To IBS And Crohn's Disease
GeneThera, Inc. (PINKSHEETS: GTHR) announced it will begin testing of raw and processed milk and dairy products using its Real Time PCR test for Johne's disease through its Wheat Ridge, CO laboratory.

New Recommendations Released For Treatment Of IBS
Although irritable bowel syndrome (IBS) is the most common disease diagnosed by gastroenterologists, it's also one of the most misunderstood. That's why updated guidelines addressing the management of the condition are being released by the American College of Gastroenterology.

Gut Instincts: What Harms Some Cells May Protect Against Inflammatory Bowel Disease
In a finding that could lead to improved treatment of chronic inflammatory bowel disease (IBD), Yale University researchers have uncovered a key mechanism in the immune system that appears to offer protection from the disorder. Their work appears in the December 19 issue of Immunity. IBD is caused by an immune response gone awry. Detecting an inflammatory threat, T helper cells, which boost the body's defense system, overreact.

Study Examines Association Of Race And Insurance Status With Presentation And Surgical Treatment Of Diverticulitis
Among patients undergoing surgery for diverticulitis, race was associated with a complicated presentation and in-hospital mortality, but not with receiving a colostomy, whereas insurance status was associated with complicated presentation, in-hospital mortality and receiving a colostomy, according to a report in the December issue of Archives of Surgery, one of the JAMA/Archives journals.

Irritable Bowel Syndrome Can Have Genetic Causes
Irritations of the bowel can have genetic causes. Researchers at the Institute of Human Genetics at Heidelberg University Hospital have discovered this correlation. The causes of what is known as irritable bowel syndrome (IBS), one of the most common disorders of the gastrointestinal tract, are considered unclear - making diagnosis and treatment extremely difficult.

Vital Clues About Cause Of Bowel Disease
Scientists have uncovered vital clues about how to treat serious bowel disorders by studying the behaviour of cells in the colon. Researchers at the University of Edinburgh believe a chemical messenger that is essential for developing a baby's gut in the womb could hold the key to new treatments for inflammatory bowel disease (IBD), a condition which affects 1 in 250 people in the UK.

Ore Pharmaceuticals Announces Completion Of Multiple Ascending Dose GL1001 Clinical Phase 1 Trial
Ore Pharmaceuticals Inc. (NASDAQ: ORXE) today announced that it has completed dosing volunteer subjects in its multiple ascending dose clinical study of the Company's lead drug candidate, GL1001. The study, initiated in September, was a blinded, placebo-controlled study in 32 healthy volunteers which studied multiple ascending doses up through the highest planned dose of 1800mg. The compound was orally administered once daily for 14 days.

Seven-Year Clinical Trial $8.5 Million Funding For Novel IBS Treatment Developed At UB
Irritable bowel syndrome is a chronic, debilitating disorder affecting 25 million people in the U.S -- 14-24 percent of women and 5-19 percent of men. No reliable and satisfactory medical treatment exists for the full range of IBS symptoms, which can cause severe physical and psychological distress and deprive sufferers of their quality of life.

Successful IBS Treatment With Peppermint Oil, Antispasmodics, And Fiber
According to a study published on bmj.com, doctors should recommend fiber, antispasmodics, and peppermint oil as first-line treatments for irritable bowel syndrome (IBS). Recent proof of the effectiveness of these treatments should also lead to changes in the national guidelines that specify how to manage IBS. Affecting between 5% and 20% of the population, IBS is a condition that causes abdominal pain and irregular bowel movements.

A Faster Test For The Food Protein That Triggers Celiac Disease - Analytical Chemistry Journal
Researchers in Spain and the United Kingdom are reporting development of a faster test for identifying the food protein that triggers celiac disease, a difficult-to-diagnose digestive disease involving the inability to digest protein called gluten that occurs in wheat, oats, rye, and barley. The finding could help millions of people avoid diarrhea, bloating, and other symptoms that occur when they unknowingly eat foods containing gluten.

Philips' Intelligent Pill Targets Drug Development And Treatment For Digestive Tract Diseases
At this week's opening of the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition (Atlanta, USA, November 16-20, 2008) Philips Research will announce its new intelligent pill technology "iPill", targeted at assisting drug development and enabling new therapies for debilitating and life-threatening digestive tract disorders such as Crohn's disease, colitis and colon cancer.

Newly Discovered Immune Cell May Help Those With Crohn's And Colitis
The tonsils and lymphoid tissues in the intestinal tract that help protect the body from external pathogens are the home base of a rare immune cell newly identified by researchers at Washington University School of Medicine in St. Louis. The researchers indicate that the immune cells could have a therapeutic role in inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis.

APRISO(TM) Granted FDA Marketing Approval For Maintenance Of Remission Of Ulcerative Colitis
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO(TM) (mesalamine) extended-release capsules 0.375 g. APRISO is a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults. APRISO is the first and only mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis.

APRISO™ Granted FDA Marketing Approval For Maintenance Of Remission Of Ulcerative Colitis
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO™ (mesalamine) extended-release capsules 0.375 g. APRISO is a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults. APRISO is the first and only mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis.